According to the results of a phase 3 study published in Blood Advances, the antisense oligonucleotide (ASO) oblimersen can be added safely to conventional chemotherapy for older patients with acute myeloid leukemia (AML), and although adding the ASO did not improve complete remission (CR) rates, it appeared to improve disease-free survival...
treatment News
BOSTON — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced a collaboration with the National Alliance on Mental Illness (NAMI), the nation’s largest grassroots mental health organization, to offer new mental health...
BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, is pleased to announce the Health Canada approval of MYALEPTA™ (metreleptin for injection). As an adjunct to diet, MYALEPTA is indicated as a...
BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness wounds...
Denver, Colorado – Four children who acquired HIV in utero have remained free of detectable HIV for more than one year, according to new findings that were presented on March 6, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colo. The study is part of ongoing, multinational...
Enrollment ongoing in atrasentan pivotal phase 3 ALIGN study in IgAN and phase 2 AFFINITY study in proteinuric glomerular diseases Chinook expects to present data from the IgAN patient cohort of the phase 2 AFFINITY study in the first half of 2022, with data from one or more additional cohorts expected...
CHENGDU, China — Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution. The trial is a multi-center,...
SOUTH PLAINFIELD, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months and older, with a clinical...
Basel – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ENSPRYNG® (satralizumab) as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody...
SYDNEY, Australia — Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that enrolment has opened for its expansion study in bile tract cancer (cholangiocarcinoma) patients, having completed the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its...